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INTRODUCTION
The worldwide prevalence of Diabetes Mellitus is rising. For western countries, it is currently projected that there will be a 17% increase in persons with Diabetes in France and Belgium by 2035 [1] , with a 22% increase in both the USA and United Kingdom, a 31% increase in Canada, and a 3% to 37% increase in other European Union countries [1] .
The most widely used class of drugs in persons with Type 2 Diabetes are the biguanides (e.g. metformin) which increase insulin sensitivity, and contribute to weight loss [2] . However, one of the side effects of metformin is to reduce vitamin B12 status. Vitamin B12 deficiency is under diagnosed and undertreated [3, 4] . Severe deficiency (e.g. pernicious anaemia) can result in macrocytic anaemia, peripheral neuropathy and mental-psychiatric changes. Also, milder symptoms such as weakness, tiredness, and memory loss can occur before frank anaemia [5] [6] [7] .
Metformin-related vitamin B12 deficiency has been known for over 40 years. However, a systematic analysis of the data concerning B12 status and metformin usage has not been carried out to date specifically in patients with Type 2 Diabetes. Two recent meta-analyses [8, 9] have shown a reduction in B12 levels in populations with metformin use but both used a mixed population of patient types (e.g. diabetes, polycystic ovary syndrome, hyperlipidaemia). Therefore, their results may differ from that of patients specifically with a diagnosis of Diabetes mellitus and a systematic review and meta-analysis is now required in this specific patient group.
Our objective was to perform the first systematic review and meta-analysis of the published literature (observational and intervention studies) on the association between metformin use and vitamin B12 deficiency (as measured by serum vitamin B12) in patients with Diabetes mellitus and to consider the potential implications for practice. 
METHOD

Primary and secondary outcomes
The primary outcomes were serum vitamin B12 levels, % prevalence or incidence of vitamin B12 deficiency and odds or risk of vitamin B12 deficiency. Diagnosis of vitamin B12 deficiency was based upon a serum vitamin B12 level below 150 pmol/l, with borderline deficiency between 150-220 pmol/l. In this paper all B12 measurements reported are that of serum vitamin B12 (pmol/L), unless otherwise stated. Secondary outcomes eligible for inclusion included reported symptoms, active B12 (Holotranscobalamin II; HoloTC), homocysteine (Hcy), methylmalonic acid (MMA), haemoglobin (Hb), mean cell volume (MCV), estimates of economic costs, and quality of life data. Due to lack of data on these secondary outcomes only the primary outcomes were included in the text of the systematic review and in the meta-analysis.
Statistical analysis
For cross-sectional surveys, mean ± standard deviation (SD) and correlation coefficients (r)
were obtained where available. Relative risk (RR), odds ratios (OR) or hazard ratios (HR)
were extracted for case-control studies, and mean and standard deviations extracted for intervention studies. The number of participants (n) as well as P values and 95% confidence intervals for effect estimates were extracted for all study types. Multivariate adjusted analyses were used where possible to reduce the effects of confounding.
Review manager (RevMan5.2, Cochrane Collaboration) [10] was used to perform the metaanalysis and for observational studies multivariate adjusted data used where possible to reduce the effects of confounding. All estimates are presented as mean ± standard deviation unless otherwise stated. The Jadad scale and CONSORT statement were used to assess the quality of the design and conduct of the randomised controlled trials (RCT's) [11] [12] [13] . The international GRADE working group grading system was used to link the quality of the evidence into recommendations [14, 15] .
RESULTS
The 26 databases identified 7257 records from which 25 studies were included in this review. For observational studies, the lack of study data, between study differences and concerns over small sample sizes prevented pooling of data to assess overall effect size. One study had both cross-sectional and cohort data [17] so is mentioned twice.
The 17 cross-sectional studies ( Table 1 ) indicated either an association of metformin use with a lower B12 concentration (10 studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] ) or showed no association (7 studies [27] [28] [29] [30] [31] [32] [33] ). In terms of cohort-based or retrospective case control studies, 4 studies were included in the review (Table 2) showing a reduction in HoloTC and total vitamin B12 [17] or increased odds of B12 deficiency after 3 years (adjusted OR=2.39 (95% CI 1.46 to 3.91) [34] in metformin users, compared with non-users. A nested case-control study [35] identified a statistically significant reduction in vitamin B12 deficiency in patients with Type 2 Diabetes with peripheral neuropathy, after 6 months of metformin usage. However, one retrospective case control study of patient notes [36] found no statistically significant difference between the incidences of vitamin B12 deficiency in patients with Diabetes who were using metformin compared with those not using metformin [36] .
Characteristics of the intervention studies, including Jadad scores are shown in Table 3 . Five intervention studies were identified [37] [38] [39] [40] [41] of which only two were double blinded, randomised and placebo controlled [37, 40] . The Hyperinsulinemia: the Outcome of its Metabolic Effects (HOME) trial was a prospective multi-centred RCT [37, 40] . This trial had a three phase process including a pre-randomisation measurement in the first 12 weeks, a post-randomisation measurement up to 16 weeks and a long-term post-randomisation phase measurement up to 4 years. At the 16-week phase there was a statistically significant fall in vitamin B12 levels of -14 % (95% CI -4.2 % vs. -24 %) in the metformin group relative to placebo (P<0.0001) [37] which dropped further to -19% (95% CI -24% to -14%) (P<0.001)
by the end of the trial at 4 years [40] . There was a 7.2 % (95% CI 2.3 to 12.1) higher absolute risk of B12 deficiency (<150 pmol/L) in the metformin group compared to placebo (P=0.004) and the corresponding number needed to harm (NNH) was 13.8 per 4.3 years (95% CI 43.5 to 8.3) [40] . Importantly, this study reported a treatment by time interaction, with vitamin B12
concentrations being more extensively lowered with a longer duration of metformin use [40] .
Meta-analysis
Four studies [38, 39, 41] [37] were suitable for inclusion in the meta-analysis. Three trials were of short duration [38, 39, 41] (≤4 months) and as the HOME trial data were present in two papers (interim analysis at 4 months [37] and final analysis at 4 years [40] ), the HOME trial 4 months measurement [37] was chosen for the meta-analysis rather than the 4 year measurement [40] . This was chosen in order for the HOME trial to be homogenous with the other trials in the meta-analysis. Due to the potential for significant study heterogeneity a meta-analysis was conducted using both fixed and random effects models.
The I 2 statistic was used to assess heterogeneity between study outcomes. A sensitivity analysis, with removal of each study in turn, showed a WMD (fixed) estimate of - 
DISCUSSION
Observational data in this review has shown lower B12 levels, and an increased risk of borderline or frank B12 deficiency with metformin use. Most intervention trials in this review were only of short duration (up to 4-months) but indicated a statistically significant reduction in B12 levels beyond the 6-weeks period and in some cases led to frank deficiency. Our fixed effects meta-analysis of four intervention trials showed a statistically significant lowering of vitamin B12 levels by 57 pmol/L(95% CI: -35 to -79).
This reduction in B12 levels could be clinically significant in causing frank deficiency concentration of <200pmol/L [42] . Accordingly, the EPIC (European Prospective
Investigation into Nutrition and Cancer) cohort in Europe has shown that 5% of adults (<60 years old) have a B12 concentration of <175pmol/L [43, 44] . According to the effect size found in our meta-analysis, it would be predicted that a significant proportion of the patients with Type 2 Diabetes in European populations are in danger of developing frank B12 deficiency or at least borderline levels of deficiency during the first four months of metformin treatment.
In terms of previous research, our results supports the recent meta-analysis by Niafar et al.
(2015) which found a reduction of 66 pmol/L (-65.8 (95% CI -78.1 to -53.6 pmol/L p<0.00001) for metformin use in an analysis of a more heterogeneous group of patients (including studies of specific groups of patients with hyperlipidaemia and polycystic ovarian syndrome) [8] . Our result is also similar to that of Liu et al (2014) [9] , who found a reduction of 54 pmol/L in a meta-analysis, but included rosiglitazone as a control in the pooled estimate. The fact that our estimate is similar to these other meta-analyses suggests that the effect of metformin on B12 may not vary by patient population studied and thus separate guidance might not be required for different clinical populations. The concordance with the other meta-analysis also supports the reliability of our effect size. Since our electronic searches were completed there have been 8 observational studies published that are relevant to our review [45] [46] [47] [48] [49] [50] [51] . All of these studies have supported a reduction in B12 status with metformin use, or higher than expected levels of deficiency in metformin using patients. Of note, Beulens et al. (2015) found both reduced vitamin B12 and holotranscobalamin in metformin users [51] . Therefore, inclusion of these articles would have been unlikely to change the overall results of our systematic review, although it is important to note that the study by de Groot-Kamphuis et al. (2013) found that metformin use was not associated with risk of neuropathy or anaemia [46] . Importantly, there have been no new intervention studies published to the authors' knowledge since the end date of our searches so our meta-analysis estimate for intervention studies can be considered up to date.
Limitations
Strengths of this work include the fact that to the author's knowledge, this is the first systematic review and meta-analysis to summarise all the research evidence for the association between metformin and vitamin B12 deficiency in patients with Type 2 Diabetes specifically. However, most of the studies in this review were conducted in outpatient clinics
and not in primary care, which limits generalizability. The wide variation in study design, wide confidence intervals in some studies, lack of standardisation of assessment of vitamin B12 status and a small number of interventional trials makes clear conclusions difficult to elucidate. Usage of a random effects model due to the presence of heterogeneity made the estimate for the B12 reducing ability of metformin slightly larger, with wider confidence intervals. Our meta-analysis only included trial measurements at ≤4 months, so may not be applicable for longer time scales. Effect sizes may differ by age group of trial participants (e.g. the lowering effect could theoretically be more profound in the elderly), but this could not be assessed in this analysis due to a lack of studies in different age groups.
There were also other limitations in terms of study quality and design for the intervention studies, with Jadad score ≤ 3 in all but one study. Only one of the intervention studies (HOME study, data in two papers [37, 40] ) met the criteria for a double blind randomised placebo controlled trial. This is likely to affect the accuracy of the meta-analysis estimate calculated. Most studies contained a small number of participants, leading to the HOME trial [37] receiving 55% of the weight in the meta-analysis. However, the sensitivity analysis showed that removal of this trial from the analysis did not greatly change the effect size. We could not conduct funnel plots to assess bias (e.g. publication bias) as we only had four studies in the review, and funnel plots are known to be less reliable for analyses based on a small number of trials, studying a small sample of individuals [52] .
Finally, due to lack of data secondary outcomes were not assessed as a part of this review but highlight a research gap warranting further study. Also there was some suggestion in three studies that dose and duration of metformin could be significant factors in determining B12 levels [34] [26, 53] . This also could not be assessed in more detail due to lack of studies reporting data for dose and duration.
Implications for research and practice
Our meta-analysis provides an assessment as to the effect size of the association between metformin and B12 status specifically in patients with Type 2 Diabetes, based on a metaanalysis of short-term therapy (up to 4 months).
Clinically, our results suggest that there is a clear need for evidence based guidelines and for examination of the implications for practice. The traditional treatment for B12 deficiency has been with parenteral therapy due to poor oral absorption. However, it is currently recognised that high dose oral B12 (1000 µcg) appears to rectify the levels in most patients [35] being as effective as parenteral therapy [54, 55] . Regular oral B12 or annual B12 injections have been recommended as safe ways to maintain levels in B12 deficient patients [55] . In addition, this review suggests the need for a cost-benefit analysis, comparing a 'watch and wait' strategy of clinical case finding versus regular vitamin B12 status checks. This should consider the management of B12 status in screened vs. unscreened patients, and the effects of this upon usage of healthcare services e.g. falls in the elderly secondary to neurological damage. [56] 
CONCLUSION
This review of patients with Type 2 Diabetes shows a reduction in B12 status by 57pmol/L after up to 4 months of metformin use, which based on European data for B12 status would be predicted to lead to frank deficiency in a significant proportion of patients. Our findings support that of a previously published meta-analyses of more heterogeneous populations of metformin users [8, 9] . A cost-benefit analysis is now required to fully investigate the most effective protocols for treating this widespread problem (e.g. watch and wait vs. clinical screening) and appropriate clinical guidelines produced. [25] (M) 
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